Form 4: Amgen EVP Reese Disposes Shares for Tax Obligations

Amgen's EVP and Chief Technology Officer, David M. Reese, reported the disposition of 6,022 common shares for tax liability at $366.21 per share.

Summary

• David M. Reese, Amgen's EVP & Chief Technology Officer, disposed of 6,022 shares of common stock.
• The transaction occurred on March 16, 2026, at a price of $366.21 per share.
• The disposition was coded as 'F', indicating it was for payment of tax liability.
• Following this transaction, Mr. Reese beneficially owns 41,787 shares of Amgen common stock directly.
• The beneficially owned shares include 744 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are paid out in shares on a one-to-one basis according to the vesting schedule.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's a disposition, it's for tax purposes, and the executive retains a substantial holding, indicating continued confidence.

Positives

• The reporting person continues to hold a significant number of shares (41,787), indicating continued alignment with shareholder interests.
• The transaction code 'F' indicates a disposition for tax liability, which is a common and expected event for executive compensation.

Negatives

• A reduction in direct share ownership by a key executive, even for tax purposes, could be perceived as a slight decrease in direct exposure to the company's stock performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Amgen's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax obligations, are routine events in the biotechnology and pharmaceutical industry. They typically do not reflect a change in an executive's outlook on the company's prospects but rather a standard part of managing equity compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related disposition by an executive, which typically has minimal direct impact on shareholder value or perception, especially given the retained holdings.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, tax-related disposition of shares by an executive and does not provide new information that would fundamentally alter the investment thesis for Amgen. The executive retains a significant stake, suggesting continued alignment with company performance. Therefore, a 'hold' recommendation is appropriate as this event is not expected to drive significant price movement or change the company's underlying value proposition.

Keywords

Amgen, AMGN, SEC Form 4, Insider Transaction, Stock Disposition, Executive Compensation, Tax Withholding, Dividend Equivalents